From 1Roswell Park Cancer Institute; 2Dana-Farber/Brigham and Women's Cancer Center; 3Duke Cancer Institute; 4The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 5Huntsman Cancer Institute at the University of Utah; 6Memorial Sloan-Kettering Cancer Center; 7Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 8Prostate Health Education Network; 9University of Washington/Seattle Cancer Care Alliance; 10Fox Chase Cancer Center; 11City of Hope Comprehensive Cancer Center; 12Massachusetts General Hospital Cancer Center; 13Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 14Vanderbilt-Ingram Cancer Center; 15University of Michigan Comprehensive Cancer Center; 16Moffitt Cancer Center; 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The University of Texas MD Anderson Cancer Center; 20Patient Advocate; 21Stanford Cancer Institute; 22Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and 24National Comprehensive Cancer Network.
J Natl Compr Canc Netw. 2013 Dec 1;11(12):1471-9. doi: 10.6004/jnccn.2013.0174.
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.
NCCN 前列腺癌指南提供了关于前列腺癌患者临床管理的多学科建议。本报告重点介绍了最近的显著更新。镭-223 二氯化物是一种首创的放射性药物，最近获得批准用于治疗有症状的骨转移且无已知内脏疾病的患者。它作为一线和二线治疗选择获得了 1 类推荐。NCCN 前列腺癌专家组还根据最近比较这两种策略在非转移性和转移性环境中的 III 期临床数据，修订了间歇性或持续性雄激素剥夺治疗选择的建议。
